|Application ||WB, IHC-P, IF, E|
|Other Accession||AAD52982, NP_006389.2|
|Calculated MW||18473 Da|
|Antigen Region||120-153 aa|
|Other Names||Ubiquitin D, Diubiquitin, Ubiquitin-like protein FAT10, UBD, FAT10|
|Target/Specificity||This FAT10 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 120-153 amino acids from the C-terminal region of human FAT10.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||FAT10 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Ubiquitin-like protein modifier which can be covalently attached to target protein and subsequently leads to their degradation by the 26S proteasome, in a NUB1L-dependent manner. Probably functions as a survival factor. Conjugation ability activated by UBA6. Promotes the expression of the proteasome subunit beta type-9 (PSMB9/LMP2). Regulates TNF-alpha-induced and LPS-mediated activation of the central mediator of innate immunity NF-kappa-B by promoting TNF-alpha-mediated proteasomal degradation of ubiquitinated-I-kappa-B-alpha. Required for TNF-alpha-induced p65 nuclear translocation in renal tubular epithelial cells (RTECs). May be involved in dendritic cell (DC) maturation, the process by which immature dendritic cells differentiate into fully competent antigen-presenting cells that initiate T-cell responses. Mediates mitotic non-disjunction and chromosome instability, in long-term in vitro culture and cancers, by abbreviating mitotic phase and impairing the kinetochore localization of MAD2L1 during the prometaphase stage of the cell cycle. May be involved in the formation of aggresomes when proteasome is saturated or impaired. Mediates apoptosis in a caspase-dependent manner, especially in renal epithelium and tubular cells during renal diseases such as polycystic kidney disease and Human immunodeficiency virus (HIV)- associated nephropathy (HIVAN).|
|Cellular Location||Nucleus. Cytoplasm Note=Accumulates in aggresomes under proteasome inhibition conditions|
|Tissue Location||Constitutively expressed in mature dendritic cells and B-cells. Mostly expressed in the reticuloendothelial system (e.g. thymus, spleen), the gastrointestinal system, kidney, lung and prostate gland.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Ucisik-Akkaya, E., et al. Mol. Hum. Reprod. 16(10):770-777(2010)
Frank, B., et al. Int. J. Cancer (2010) In press :
Gong, P., et al. J. Am. Soc. Nephrol. 21(2):316-326(2010)
Castellanos-Rubio, A., et al. Hum. Immunol. 71(1):96-99(2010)
Barcellos, L.F., et al. PLoS Genet. 5 (10), E1000696 (2009) :
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.